Arthritis Res Ther. 2009;11(6):132. Epub 2009 Nov 6.

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?

Abstract

Modulatory cytokines such as IL-4 and IL-10 looked promising biologicals, but suffered from poor exposure at the inflamed joints when administered via the patient-friendly subcutaneous route. Immunocytokines have now been engineered with tissue targeting potential and are a possible solution to this problem, although challenges still exist. Local inflammatory processes cause destruction of extracellular matrix (ECM) components, leading to neo-eptitopes, and/or elicit the synthesis of new ECM components. This makes ECM elements interesting targets for antibody-mediated recognition and retention, to achieve higher levels of immunocytokines at the site of therapeutic interference. The study presented by Schwager and colleagues shows that targeted delivery of IL-10 is more efficacious in experimental arthritis. Clinical studies are warranted to show whether this strategy works for all rheumatoid arthritis patients or is better for subgroups with a defined ECM phenotype. In principle, the scFv-targeting system is plastic enough to allow for personalized strategies.

PMID:: 19903325; [PubMed - indexed for MEDLINE]
PMCID:: PMC3003506

Free PMC Article

Publication Types, MeSH Terms, Substances

Publication Types

Editorial

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Review Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. [Rheum Dis Clin North Am. 2002]
Review Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators.
van de Loo FA, van den Berg WB. Rheum Dis Clin North Am. 2002 Feb; 28(1):127-49.
Review Targeted therapy in rheumatoid arthritis. [Wien Med Wochenschr. 2006]
Review Targeted therapy in rheumatoid arthritis.
Köller MD. Wien Med Wochenschr. 2006 Jan; 156(1-2):53-60.
Review Drug delivery systems for the treatment of rheumatoid arthritis. [Expert Opin Drug Deliv. 2008]
Review Drug delivery systems for the treatment of rheumatoid arthritis.
Tarner IH, Müller-Ladner U. Expert Opin Drug Deliv. 2008 Sep; 5(9):1027-37.
Review IL-17 as a future therapeutic target for rheumatoid arthritis. [Nat Rev Rheumatol. 2009]
Review IL-17 as a future therapeutic target for rheumatoid arthritis.
van den Berg WB, Miossec P. Nat Rev Rheumatol. 2009 Oct; 5(10):549-53.
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. [Arthritis Res Ther. 2009]
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.
Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E. Arthritis Res Ther. 2009; 11(5):R142. Epub 2009 Sep 25.

See reviews... See all...

Cited by 1 PubMed Central article

The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. [Arthritis Rheum. 2010]
The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.
Deane KD, O'Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, Gilliland WR, Edison JD, Norris JM, Robinson WH, et al. Arthritis Rheum. 2010 Nov; 62(11):3161-72.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthrit...
Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?
Arthritis Res Ther. 2009 ;11(6):132. Epub 2009 Nov 6 .

PubMed
Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell...
Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy.
Arthritis Rheum. 1991 Mar ;34(3):351-6.

PubMed
Active immunization to tumor necrosis factor-alpha is effective in treating chro...
Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.
Arthritis Res Ther. 2009 ;11(6):R195. Epub 2009 Dec 23 .

PubMed
Chemical composition and swelling of normal and osteoarthrotic femoral head cart...
Chemical composition and swelling of normal and osteoarthrotic femoral head cartilage. II. Swelling.
Ann Rheum Dis. 1977 Oct ;36(5):399-406.

PubMed
Interleukin-23 is critical for full-blown expression of a non-autoimmune destruc...
Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells.
Arthritis Res Ther. 2009 ;11(6):R194. Epub 2009 Dec 17 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: